Remote prescribing requires more than a valid prescription
Regulatory and clinical-governance advisory for digital services where medicines are assessed, prescribed, supplied or monitored remotely.
Remote prescribing changes the information available to the clinician, the way decisions are made and the evidence a provider must be able to demonstrate.
Remote prescribing changes the clinical pathway
Remote prescribing may depend on information obtained through online questionnaires, telephone or video consultation, uploaded evidence and third-party systems. The prescriber may have limited access to the wider clinical record and may not have physically examined the patient.
Where prescribing and dispensing sit with different organisations, further questions arise around responsibility, information sharing, escalation, monitoring and continuity of care.
The professional standard does not become lower because prescribing takes place remotely. The service model must enable clinicians to determine when remote assessment is sufficient — and when it is not.
Online prescribing is not simply prescribing through a different communication channel
The safety of a remote prescribing decision depends on the quality and reliability of the information available to the prescriber.
Oxara examines whether the service model supports clinically defensible prescribing decisions, including circumstances where further information, a different consultation method or another clinical pathway may be required.
Some medicines and prescribing models require additional safeguards, particularly where treatment requires monitoring, prescribing is repeated, medicines carry significant potential for harm or misuse, or controlled drugs are within scope.
Governance should reflect the actual risk profile of the service rather than relying on a generic medicines policy.
Digital services may separate assessment and prescribing from dispensing and supply.
Oxara examines whether accountability remains clear across the provider, prescriber and dispensing pharmacy, and whether the arrangements support safe information exchange, clinical escalation and continuity when the pathway does not proceed as expected.
Remote prescribing can become an isolated episode of care where information does not connect with the patient's wider clinical record.
Follow-up, treatment response, monitoring, repeat prescribing and communication with other clinicians therefore form part of the governance picture — particularly where ongoing treatment or additional safeguards are required.
When technology becomes part of the clinical risk
Digital prescribing systems may do considerably more than connect a clinician and patient.
Online questionnaires, eligibility logic, alerts, clinical decision support and other automated functions can influence what information reaches the prescriber and what happens next.
Where technology materially influences clinical care, the governance position may extend beyond ordinary information security to digital clinical safety and, depending upon the technology's function, other regulatory requirements.
Current NHS clinical-safety arrangements include DCB0129 for manufacturers of health IT and DCB0160 for organisations deploying and using it. These standards are currently undergoing national review.
Where technology influences a clinical decision, technology governance becomes clinical governance
Provider oversight must extend beyond the individual prescriber
Safe prescribing is a professional responsibility. But professional registration alone does not establish that the system surrounding the prescriber is safe.
Oxara examines whether prescribing activity, clinical records, incidents, audit, safeguarding concerns, third-party performance and governance evidence provide meaningful assurance about how the service is operating.
A service can employ appropriately registered clinicians and still have weaknesses in the system within which they prescribe
Regulatory review of the proposed service, clinical pathway and supporting registration evidence.
Independent review of whether written governance, clinical practice and provider oversight reflect the way medicines are actually prescribed and managed.
Review of accountability and governance where prescribing, dispensing and supply cross organisational boundaries.
Evidence review before regulatory scrutiny or significant service change, and support where prescribing or medicines governance has become an area of regulatory concern.
Planning or reviewing a remote prescribing service?
Discuss Your Remote Prescribing ModelThe evidence must reflect the service that actually operates
A remote-prescribing policy cannot establish safe governance by itself.
Oxara examines whether the clinical pathway, prescribing activity, records and organisational oversight support the regulatory position the provider is presenting.
The question is not simply whether the provider has documented its arrangements.
It is whether the evidence demonstrates that those arrangements operate in practice
Where this work connects
Regulatory and governance advisory for online and hybrid primary care services where clinical assessment, triage, escalation and continuity are delivered remotely.
Strengthening governance systems and the evidence that demonstrates leadership oversight of a regulated service.
Regulatory and governance advisory for digital diagnostic, screening and monitoring pathways where clinical information is obtained, interpreted or acted upon remotely.
Remote prescribing and regulation
Does CQC regulate online prescribing services?
CQC regulates online primary care providers in England where regulated activities fall within its scope. Online prescribing may form part of those services, while dispensing by a pharmacy sits within a different regulatory framework. The precise position depends on the service model and where responsibility for regulated activity sits.
Are the prescribing standards different for a remote consultation?
No. Clinicians must provide safe and effective care whether the consultation is face to face, by telephone, video or another online method. The consultation method must be appropriate to the patient and support a safe prescribing decision.
Does using a separate dispensing pharmacy remove the provider's responsibility?
No. Separating parts of the pathway between organisations does not remove the need for clear accountability, safe information exchange and effective governance across the patient's care.
When does digital clinical safety become relevant?
It can become relevant where health IT affects clinical care or patient safety — for example, systems supporting clinical decisions or the deployment and use of digital healthcare technology. Which requirements apply depends upon the technology and how it is used.
Can Oxara review an existing remote prescribing service?
Yes. Oxara can review established services as well as models being developed or prepared for CQC registration, including where prescribing governance has become an area of regulatory concern.
Remote prescribing model under development or review?
Whether you are preparing a new digital service, reviewing an established prescribing pathway or responding to regulatory concern, speak directly with Oxara about the governance and regulatory position.